Arginine

Arginine

SCHEMBL1675351

C[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.50
NOS2 P35228 8/20 0.49
NOS1 P29475 8/20 0.49
NOS3 P29474 6/20 0.49
DDAH1 O94760 3/20 0.47
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GSR P00390 1/20 0.43
CYP1A2 P05177 2/20 0.42
TSHR P16473 2/20 0.42
CYP3A4 P08684 1/20 0.42
GLA P06280 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
BLM P54132 1/20 0.41
NOD1 Q9Y239 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL5544125 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL9754275 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL5544129 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL1821002 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL2787541 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL2397458 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL5312506 1.00 OTC (0.50) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL15323423 0.97 OTC (0.48) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL11018148 0.97 OTC (0.48) OTCNOS2NOS1NOS3DDAH1
Arginine SCHEMBL15323426 0.97 OTC (0.48) OTCNOS2NOS1NOS3DDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117789993-B Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-06-11 CN claimed
CN-117789993-A Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-03-29 CN claimed
WO-2024013258-A1 PRODUCTION OF CYSTEINE OR CYSTINE FROM SERINE IN FERMENTATION MEDIUM CYSBIO APS (DK) 2024-01-18 WO claimed
CN-114137226-B Early diagnosis marker for cerebral infarction, screening method and application thereof, and construction method and application of early diagnosis model for cerebral infarction 首都师范大学 2023-04-28 CN claimed
CN-114137226-A Marker for early diagnosis of cerebral infarction, screening method and application thereof, and construction method and application of model for early diagnosis of cerebral infarction 首都师范大学 2022-03-04 CN claimed
CN-110063313-A A kind of oxygenation bait and preparation method thereof with comprehensive high-tech attracting 威海猎屋渔具有限公司 2019-07-30 CN claimed
US-20150293023-A1 SYSTEMS AND METHODS FOR MEASURING TRANSLATION OF TARGET PROTEINS IN CELLS ANIMA CELL METROLOGY, INC. 2015-10-15 US claimed
WO-2014026143-A1 CONJUGATED ANTI-MICROBIAL COMPOUNDS AND CONJUGATED ANTI-CANCER COMPOUNDS AND USES THEREOF PONO CORPORATION (US) 2014-02-13 WO claimed
US-20120183957-A1 SYSTEMS AND METHODS FOR MEASURING TRANSLATION OF TARGET PROTEINS IN CELLS ANIMA CELL METROLOGY, INC. (US) 2012-07-19 US claimed
US-20060275803-A1 Rat and mouse members of the CRISP family of genes WYETH (US) 2006-12-07 US claimed
WO-2006119461-A2 RAT AND MOUSE MEMBERS OF THE CRISP FAMILY OF GENES WYETH (US) 2006-11-09 WO claimed
EP-1562578-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE TO EXTRACORPOREAL AND ISOLATED ORGANS Hemocorm Limited (GB) 2005-08-17 EP claimed
WO-2004045598-A1 THERAPEUTIC DELIVERY OF CARBON MONOXIDE TO EXTRACORPOREAL AND ISOLATED ORGANS HEMOCORM LIMITED (GB) 2004-06-03 WO claimed
EP-0923287-A4 NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES LILLY CO ELI (US) 2001-08-01 EP claimed
EP-0923287-A1 NONCLASSICAL PYRROLO 2,3-D]PYRIMIDINE ANTIFOLATES ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
WO-1998008382-A1 NONCLASSICAL PYRROLO[2,3-D]PYRIMIDINE ANTIFOLATES ELI LILLY AND COMPANY (US) 1998-03-05 WO claimed
CN-115746110-B Mutant of transcription control factor LysG and application thereof 中国科学院天津工业生物技术研究所 2024-10-18 CN disclosed
US-20240229079-A9 ENGINEERED TARGET SPECIFIC NUCLEASES SANGAMO THERAPEUTICS INC (US) 2024-07-11 US disclosed
EP-0199574-A2 Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants GENENTECH, INC. (US) 1986-10-29 EP disclosed
WO-1986005208-A1 POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS HAVING AN AMINO ACID SEQUENCE OR NUCLEOTIDE CODING SEQUENCE AT LEAST PARTIALLY KNOWN AND METHODS OF DESIGN THEREFOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1986-09-12 WO disclosed